Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?—Autophagy Inhibition Matches the Mismatched

The oncologist

article

Chun-Yi Tsai¹  Tien-An Lin¹  Shih-Chiang Huang²  Jun-Te Hsu¹  Chun-Nan Yeh¹  Tse-Ching Chen²  Cheng-Tang Chiu³  Jen-Shi Chen¹  Ta-Sen Yeh¹ 

[1] Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine;Department of Pathology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine;Department of Gastroenterology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine

关键词: Microsatellite instability;    Mismatch repair;    Gastric cancer;    Autophagy;   

DOI  :  10.1634/theoncologist.2019-0419

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Purpose The use of microsatellite instability (MSI) and mismatch repair (MMR) as predictive biomarkers for fluorouracil-based adjuvant chemotherapy in colorectal cancer has been a paradigm shift. However, whether this applies to gastric cancer is questionable. Furthermore, we herein investigated whether and how autophagy plays a role in MSI-relevant chemoresistance. Materials and Methods A total of 929 patients with deficient MMR (dMMR) and proficient MMR (pMMR) gastric cancers who underwent curative-intent gastrectomy were enrolled. We compared clinicopathological variables and survival among dMMR and pMMR cohorts and tested the responses of MSI-high and microsatellite stable (MSS) gastric cancer cell lines to 5-fluorouracil (5-FU) with or without chloroquine, an autophagy inhibitor. Results We identified an 8.9% prevalence of dMMR cases (83 out of 929) in our cohort. This was associated with old age, tumor site at the distal stomach, an intestinal phenotype, fewer nodal metastasis, and early pathological stages. MMR was an independent prognostic factor after multivariate adjustment. Overall survival (OS) of dMMR patients was better than that of the pMMR patients but was only applicable to stage III patients. There was no difference in OS between dMMR patients treated with or without adjuvant chemotherapy, although the latter showed more medical morbidities. The MSI-high gastric cancer cell lines, versus the MSS counterparts, displayed increased resistance to 5-FU and increased autophagy. Interestingly, autophagy inhibition abrogated the chemoresistance. Conclusion Our data show that fluorouracil-based adjuvant chemotherapy does not work for dMMR cases, if not worse. Autophagy inhibition and/or immune checkpoint inhibition might be promising alternative strategies for gastric cancer treatment. Implications for Practice The use of microsatellite instability (MSI) and mismatch repair (MMR) as predictive biomarkers for adjuvant chemotherapy in colorectal cancer has caused a paradigm shift in cancer therapy, although its implications in gastric cancer are still questionable. The data obtained in the current study indicate that MSI-MMR is an independent prognostic factor for gastric cancer. Standard fluorouracil-based adjuvant chemotherapy did not work for deficient MMR cases, and was likely worse. Instead, strategies like autophagy inhibition and/or immune checkpoint inhibition should be taken into consideration in the future.

【 授权许可】

CC BY|CC BY-NC